PTO/SB/08a (07-09) Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10582304
Filing Date		2007-04-20
First Named Inventor	Kimur	a et al.
Art Unit		1643
Examiner Name	Anne Gussow	
Attorney Docket Number	ər	14875-0166US1

					0.5.1	PAIENIS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where	
/AMG/	1	7115373	B2	2009-10	1-27	HASHIDA et al.					
If you wis	h to ac	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P.	ATENT	APPLI	CATION PUBL	ICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where	
/AMG/	1	20090297501	A1	2009-12	!- <b>0</b> 3	IGAWA et al.					
	2	20030103979	A1	2003-06-05		LEUNG et al.					
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIC	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	T5
/AMG/	1	WO97034632	wo			1997-09-25	LEUNG et al.				
/AMG/	2	WO03002607	wo		A1	2003-01-09	LEUNG et al.				

....

/Anne M. Gussow/ 03/11/2010

STATEMENT BY APPLICANT	
Not for submission under 37 CFR 1.99)	

Application Number		10582304
Filing Date		2007-04-20
First Named Inventor	Kimur	ra et al.
Art Unit		1643
Examiner Name	Anne Gussow	
Attornov Dooket Numb	or	14875.01661191

/AMG/	3	JP10508868	JP		1998-09-02	UCKUN et al.		
/AMG/	4	JP2005529616	JP		2005-10-06	DEVERAUX et al.		
/AMG/	5	WO02028894	wo		2002-04-11	KOMATANI et al.		
/AMG/	6	WO2005004912	wo		2005-01-20	NAKAMURA et al.		
/AMG/	7	WO2008007755	wo		2008-01-17	KIMURA et al.		
If you wis	h to a	dd additional Foreign	Patent Docume	ent citation	information p	lease click the Add button	Add	•
			NON-PA	TENT LITI	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
/AMG/	1	SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," Current Opinion in Hematology, 12:444-450 (2005)						
/AMG/	2	U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed  October 19, 2009, 6 pages						
/AMG/	3	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed October 27, 2009, 4 pages						
/AMG/	4	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page						

/Anne M. Gussow/ 03/11/2010

( Not for submission under 37 CFR 1.99)

Application Number		10582304
Filing Date		2007-04-20
First Named Inventor Kimur		a et al.
Art Unit		1643
Examiner Name	Anne Gussow	
Attorney Docket Number		14875-0166US1

			_
/AMG/	5	BORDEN et al., "Lymphokines and Cytokines as Cancer Treatment," Cancer, 65:800-814 (1990)	
/AMG/	6	BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," CA Cancer J. Clin., 49:353-361 (1999)	
/AMG/	7	GRANZIERO et al., "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," Eur. J. Immunol., 29:1127-1138 (1999)	
/AMG/	8	U.S. EXAMINER ELLY GERALD STOICA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages	
/AMG/	9	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/548,727, mailed November 25, 2009, 29 pages	
/AMG/	10	FISH & RICHARDSON, Amendment in Reply to Action dated June 8, 2009 in U.S. App. Ser. No. 10/530,696, filed November 30, 2009, 10 pages	
/AMG/	11	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 1, 2009 in U.S. App. Ser. No. 11/547,747, filed November 30, 2009, 12 pages	
/AMG/	12	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 2, 2009, 4 pages	
/AMG/	13	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed December 8, 2009, 33 pages	
/AMG/	14	FISK et al., "Increased sensitivity of Adriamycin-selected Tumor Lines to CTL-mediated Lysis Results in Enhanced Drug Sensitivity," Cancer Res., 58:4790-4793 (1998)	
/AMG/	15	JALILI et al., "Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells," Blood (ASH Annual Meeting Abstracts), 118 (11):701a-702a (#2376) (2007)	

FS Web 2 1.16 /Anne M. Gussow/

( Not for submission under 37 CFR 1.99)

Application Number		10582304
Filing Date		2007-04-20
First Named Inventor	Kimur	ra et al.
Art Unit		1643
Examiner Name	Anne	Gussow
Attorney Docket Numb	er	14875-0166US1

/AMG/	16	MELGUIZO et al., "Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells," Neoplasma, 50(2):91-96 (2003)	
/AMG/	17	OZAKI et al., "Induction of myeloma cell death by a recombinant HLA class I-specific single-chain Fv diabody," Dai 65 Nihon Ketsueki Gakkai, Dai 45 kai Nihon Ketsueki Gakkai Sokai, Osaka (August 28-31, 2003)	×
/AMG/	18	OZAKI et al., "A recombinant HLA class I-specific single chain Fv diabody induces cell death in human lymphoid malignancies," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003)	
/AMG/	19	PRADOS et al., "Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase," Neoplasma, 53(3):226-231 (2006)	
/AMG/	20	SEKIMOTO et al., "Eradication of human myeloma cells by a recombinant HLA class I-specific single chain Fv diabody," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003)	
/AMG/	21	SONNEVELD, "Multidrug resistance in haematological malignancies," J. Intern. Med., 247:521-534 (2000)	
/AMG/	22	TSUKAKOSHI, New Pharmacology, 3rd revised edition, Nankodo Co., Ltd., 557-568 (1997)	
/AMG/	23	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2008/054443, dated May 27, 2008, 7 pages	
/AMG/	24	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed January 7, 2010, 46 pages	
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	
Examine	Sign	ature /Anne M. Gussow/ Date Considered 03/11/2010	
*EXAMIN	IER: I	nitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a	

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

( Not for submission under 37 CFR 1.99)

Application Number		10582304	
Filing Date		2007-04-20	
First Named Inventor Kimur		ra et al.	
Art Unit		1643	
Examiner Name	Anne	Gussow	
Attorney Docket Number		14875-0166US1	

<sup>1</sup> See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by appropriate symbios as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.